Learn how artificial intelligence has the potential to revolutionize drug discovery and the material sciences that have evolved the pharmaceutical industry.
Table of ContentsIntroduction
1. The Role of ML and DL in Envisioning Drug Effectiveness and Toxicity
1.1. Machine learning in drug discovery
1.2. Deep learning in drug discovery
2. The Collaborative Role between AI Researchers and Pharmaceutical Scientists
3. Ethical Considerations Regarding the Use of AI in the Pharmaceutical Industry
Wrapping Up
Introduction
In recent years, artificial intelligence (AI) in the pharmaceutical industry has gained significant traction, especially in the drug discovery field, as this technology can identify and develop new medications, helping AI researchers and pharmaceutical scientists eliminate the traditional and labor-intensive techniques of trial-and-error experimentation and high-throughput screening.
The successful application of AI techniques and their subsets, such as machine learning (ML) and natural language processing (NLP), also offers the potential to accelerate and improve the conventional method of accurate data analysis for large data sets. AI and ML-based methods such as deep learning (DL) predict the efficacy of drug compounds to understand the accrual and target audience of drug use.
For example, today’s virtual chemical databases contain characterized and identified compounds. With the support of AI technologies along with high-performance quantum computing and hybrid cloud technologies, pharmaceutical scientists can accelerate drug discovery through existing data and the experimentation and testing of hypothesized drugs, which leads to knowledge generation and the creation of new hypotheses.
In today’s AI Tech Park article, we will discuss the role of AI in drug discovery and materials science, the impact of AI on the drug discovery process, and potential cost savings.
1. The Role of ML and DL in Envisioning Drug Effectiveness and Toxicity
In this section, we will understand the role of the two most important technologies, i.e., machine learning and deep learning, which have helped both AI researchers and pharmaceutical scientists develop and discover new drugs without any challenges:
1.1. Machine learning in drug discovery
Drug discovery is an intricate and lengthy process that requires the utmost attention to identify potential drug candidates that can effectively treat various acute and chronic drugs, which can transform the pharmaceutical industry by speeding up the prediction of toxicity and efficacy of potential drug compounds, improving precision, and decreasing costs. Based on the large set of data, ML algorithms can identify trends and patterns that may not be visible to pharma scientists, which enables the proposal of new bioactive compounds that offer minimum side effects in a faster process. This significant contribution prevents the toxicity of potential drug compounds by addressing whether the drug interacts with the drug candidates and how the novel drug pairs with other drugs.
1.2. Deep learning in drug discovery
Deep learning (DL) is a specialized form of machine learning that uses artificial neural networks to learn and examine data. The DL models in the pharmaceutical industry have different algorithms and multiple layers of neural networks that read unstructured and raw data, eliminating the laborious work of AI engineers and pharma scientists. The DL model can handle complex data through images, texts, and sequences, especially during “screen polymers for gene delivery in silico.” These data were further used to train and evaluate several state-of-the-art ML algorithms for developing structured “PBAE polymers in a machine-readable format.”
2. The Collaborative Role between AI Researchers and Pharmaceutical Scientists
The collaborative role between pharmaceutical scientists and AI researchers is essential to developing innovative and effective drugs to treat various diseases. Combining their expertise and knowledge, they can generate powerful algorithms and ML models that predict the efficacy of drug candidates, speed up the clinical trial process, and understand the adverse effects of the drug being tested.
This process will help pharma companies make informed decisions and improve the accessibility and affordability of medicines for the healthcare sector. For example, “Reactome,” an AI-powered platform developed by Pfizer and the University of Cambridge, is inspired by genomics, where automated experiments are combined with machine learning to understand chemical reactions. The ‘Reactome’ approach further validates a dataset of more than 39000 pharma-relevant chemical reactions that enable both AI researchers and pharma scientists to get a broad understanding of the chemical and make alternative medicines that will benefit future inventions.
Read more about how AI supports providing personalized healthcare to patients:
https://ai-techpark.com/ai-in-healthcare/
3. Ethical Considerations Regarding the Use of AI in the Pharmaceutical Industry
Despite the potential benefits of the utilization of AI in drug discovery, there are several challenges and ethical considerations AI researchers and pharma scientists need to face. The most common challenge is limited low-quality, and inconsistent data that affect providing accurate and reliable results, which may also raise questions about data privacy and security. As AI models depend on a large set of data to operate the process, there are risks that hackers could misuse or access sensitive information. Consequently, it might hamper the individuals and reputation of the company; therefore, post-collection and use of medical data, all pharmaceutical companies should follow the regulations while performing any experiment using AI models.
Another challenging concern is that AI-based approaches may raise concerns about being biased and providing fair results, resulting in unequal access to medical treatment and unfair treatment of certain patients, further raising the question of equality and justice. In cases where pharmaceutical companies fail to adhere to regulations, they can be severely fined, and/or their medical licenses might get nullified.
Overall, the ethical considerations of AI in the pharmaceutical industry must be carefully reviewed and adopted, keeping in mind the concerns that AI researchers and pharma scientists have to face. For a seamless drug review process, the top-level managers of pharmaceutical companies need to train their employees and explain to them that they should review and audit the AI models manually in case any bias is found. Furthermore, to eliminate the concern of
Wrapping Up
To sum up, artificial intelligence has the potential to revolutionize the drug discovery process, which helps in improving efficacy and accuracy, eradicating the problem of drug development, and providing personalized treatment to all patients. However, the dependence on a successful drug discovery depends on the availability of high-quality data, addressing personal ethical concerns, and recognizing the limitations that AI researchers and philosophers might face when they opt for an AI-based approach.
On the other hand, recent developments in AI have offered promising strategies to overcome the limitations of AI by integrating explainable AI (XAI), ML, big data, natural learning processes (NLP), and data augmentation. Combining these technologies will unlock the potential of AI drug discovery more quickly and efficiently.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
